Compare NBY & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBY | BWAY |
|---|---|---|
| Founded | 2000 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.6M | 450.8M |
| IPO Year | 2007 | N/A |
| Metric | NBY | BWAY |
|---|---|---|
| Price | $1.95 | $15.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.25 |
| AVG Volume (30 Days) | ★ 409.8K | 170.6K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.42 | N/A |
| EPS | ★ 0.76 | N/A |
| Revenue | ★ $370,000.00 | N/A |
| Revenue This Year | N/A | $309.69 |
| Revenue Next Year | N/A | $26.21 |
| P/E Ratio | ★ $2.57 | $81.98 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.43 | $7.84 |
| 52 Week High | $19.95 | $26.63 |
| Indicator | NBY | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 57.82 | 53.32 |
| Support Level | $1.01 | $14.56 |
| Resistance Level | $2.52 | $16.63 |
| Average True Range (ATR) | 0.26 | 0.74 |
| MACD | 0.11 | 0.56 |
| Stochastic Oscillator | 96.45 | 78.33 |
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.